Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2024

Open Access 01-12-2024 | Research

Multi-omics sequencing revealed endostar combined with cisplatin treated non small cell lung cancer via anti-angiogenesis

Authors: Yufei Wang, Hong Ren

Published in: BMC Cancer | Issue 1/2024

Login to get access

Abstract

Background

Endostar, an anti-angiogenic drug, has been approved for treating non-small cell lung cancer (NSCLC). At present, endostar combined with radiotherapy or chemotherapy has achieved ideal results in the treatment of some tumors, but there is a lack of application and study in NSCLC. This study investigated the therapeutic effect and potential mechanism of endostar combined with cisplatin (EC) in NSCLC.

Methods

HE staining, TUNEL staining, immunofluorescence, colony formation ability, and cell migration ability were used to evaluate the anti-tumor activity of EC. The expressions of FMOD, VEGF, FGF-2, and PDGF-B were detected by western blotting and qPCR. The target of combination therapy was analyzed by m6A sequencing and RNA sequencing. METTL3 knockdown and overexpressed A549 cells were constructed and co-cultured with HUVECs to further evaluate the effect of METLL3 on combination therapy.

Results

Combination therapy significantly reduced the colony formation and migration ability of NSCLC cells, induced cell apoptosis, and inhibited the tube formation ability of HUVECs. The results of m6A sequencing and RNA sequencing showed that the EC could down-regulate the expression level of FMOD in tumor tissues, which might be related to the reduction of its m6A methylation modification regulatory enzyme METTL3. Restricting FMOD expression could reduce the expression of FGF2, TGF-β1, VEGF and PDGF-B. Moreover, overexpression of METTLE almost abolished the anti-tumor effect of EC and promoted angiogenesis.

Conclusions

Endostar combined with cisplatin might exert anti-tumor effects by down-regulating the expression of METTL3 and FMOD.
Appendix
Available only for authorised users
Literature
1.
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer statistics 2020: GLOBOCAN estimates of incidence and Mortality Worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.PubMedCrossRef
2.
3.
Russell E, Conroy MJ, Barr MP. Harnessing natural killer cells in Non-small Cell Lung Cancer. Cells. 2022;11(4).
4.
Cagle PT, Allen TC, Olsen RJ. Lung cancer biomarkers: present status and future developments. Arch Pathol Lab Med. 2013;137(9):1191–8.PubMedCrossRef
5.
Xiong A, Wang J, Zhou C. Immunotherapy in the First-Line treatment of NSCLC: current status and future directions in China. Front Oncol. 2021;11:757993.PubMedPubMedCentralCrossRef
6.
Wu YL, Wang CL, Liao ML, Guan ZZ, Gao CY, Lu S, et al. A consensus on immunotherapy from the 2017 Chinese Lung Cancer Summit expert panel. Transl Lung Cancer Res. 2018;7(3):428–36.PubMedPubMedCentralCrossRef
7.
Folkman J. Role of angiogenesis in Tumor growth and Metastasis. Semin Oncol. 2002;29(6 Suppl 16):15–8.PubMedCrossRef
8.
Ao Z, Yu S, Qian P, Gao W, Guo R, Dong X, et al. Tumor angiogenesis of SCLC inhibited by decreased expression of FMOD via downregulating angiogenic factors of endothelial cells. Biomed Pharmacother. 2017;87:539–47.PubMedCrossRef
9.
Mondal B, Patil V, Shwetha SD, Sravani K, Hegde AS, Arivazhagan A, et al. Integrative functional genomic analysis identifies epigenetically regulated fibromodulin as an essential gene for glioma cell migration. Oncogene. 2017;36(1):71–83.PubMedCrossRef
10.
Chen M, Ba H, Lu C, Dai J, Sun J. Glial cell line-derived neurotrophic factor (GDNF) promotes angiogenesis through the demethylation of the fibromodulin (FMOD) promoter in Glioblastoma. Med Sci Monit. 2018;24:6137–43.PubMedPubMedCentralCrossRef
11.
An J, Lv W. Endostar (rh-endostatin) versus placebo in combination with vinorelbine plus cisplatin chemotherapy regimen in treatment of advanced non-small cell Lung cancer: a meta-analysis. Thorac Cancer. 2018;9(5):606–12.PubMedPubMedCentralCrossRef
12.
Ling Y, Yang Y, Lu N, You QD, Wang S, Gao Y, et al. Endostar, a novel recombinant human endostatin, exerts antiangiogenic effect via blocking VEGF-induced tyrosine phosphorylation of KDR/Flk-1 of endothelial cells. Biochem Biophys Res Commun. 2007;361(1):79–84.PubMedCrossRef
13.
Sun W, He G, Zhang M, Zhao Y, Yu H, Li Y, et al. (99m)Tc-3PRGD(2) SPECT predicts the outcome of Endostar and Cisplatin Therapy in Xenograft animals. Dose Response. 2019;17(4):1559325819882544.PubMedPubMedCentralCrossRef
14.
Yin Y, Zhou Z, Li Z, Shen M, Qin Y, Yang C, et al. Efficacy of concurrent chemoradiotherapy plus Endostar compared with concurrent chemoradiotherapy in the treatment of locally advanced nasopharyngeal carcinoma: a retrospective study. Radiat Oncol. 2022;17(1):135.PubMedPubMedCentralCrossRef
15.
Ding Y, Wang Y, Cui J, Si T. Endostar blocks the Metastasis, invasion and angiogenesis of Ovarian cancer cells. Neoplasma. 2020;67(3):595–603.PubMedCrossRef
16.
17.
Zheng AW, Jia DD, Xia LM, Jin G, Wu H, Li T. Impact of carboplatin plus paclitaxel combined with endostar against A375 Melanoma cells: an in vitro and in vivo analysis. Biomed Pharmacother. 2016;83:1321–6.PubMedCrossRef
18.
Shen Q, Xu Z, Xu S. Long non–coding RNA LUCAT1 contributes to cisplatin resistance by regulating the miR–514a–3p/ULK1 axis in human non–small cell Lung cancer. Int J Oncol. 2020;57(4):967–79.PubMedPubMedCentral
19.
Nagasawa S, Takahashi J, Suzuki G, Hideya Y, Yamada K. Why concurrent CDDP and Radiotherapy has synergistic Antitumor effects: a review of in Vitro Experimental and clinical-based studies. Int J Mol Sci. 2021;22(6).
20.
Dasari S, Njiki S, Mbemi A, Yedjou CG, Tchounwou PB. Pharmacological effects of Cisplatin Combination with Natural products in Cancer Chemotherapy. Int J Mol Sci. 2022;23(3).
21.
Zhao X, Pan J, Song Y, Ding H, Qin L, Pan Y. Recombined human endostatin (Endostar) enhances cisplatin delivery and potentiates chemotherapy by decompressing Colorectal cancer vessels. Int J Clin Exp Pathol. 2017;10(11):10792–801.PubMedPubMedCentral
22.
Guan L. Endostar Rebuilding Vascular Homeostasis and enhancing Chemotherapy Efficacy in Cervical Cancer Treatment. Onco Targets Ther. 2020;13:12811–27.PubMedPubMedCentralCrossRef
23.
Jin T, Jiang F, Jin QF, Piao YF, Chen XZ. Endostar Combined with Gemcitabine and Cisplatin Chemotherapy for patients with metastatic nasopharyngeal carcinoma: an update. Transl Oncol. 2018;11(2):286–91.PubMedPubMedCentralCrossRef
24.
Zhang Z, Wang Q, Zhang M, Zhang W, Zhao L, Yang C, et al. Comprehensive analysis of the transcriptome-wide m6A methylome in Colorectal cancer by MeRIP sequencing. Epigenetics. 2021;16(4):425–35.PubMedCrossRef
25.
Wang Y, Zeng L, Liang C, Zan R, Ji W, Zhang Z, et al. Integrated analysis of transcriptome-wide m(6)a methylome of osteosarcoma stem cells enriched by chemotherapy. Epigenomics. 2019;11(15):1693–715.PubMedCrossRef
26.
Lv C, Ren C, Yu Y, Yin H, Huang C, Yang G et al. Wentilactone A reverses the NF-kappaB/ECM1 Signaling-Induced Cisplatin Resistance through Inhibition of IKK/IkappaB in Ovarian Cancer cells. Nutrients. 2022;14(18).
27.
Li XQ, Ren ZX, Li K, Huang JJ, Huang ZT, Zhou TR et al. Key Anti-fibrosis Associated Long Noncoding RNAs identified in human hepatic stellate cell via Transcriptome Sequencing Analysis. Int J Mol Sci. 2018;19(3).
28.
29.
Kanehisa M, Furumichi M, Sato Y, Ishiguro-Watanabe M, Tanabe M. KEGG: integrating viruses and cellular organisms. Nucleic Acids Res. 2021;49(D1):D545–D51.PubMedCrossRef
30.
31.
Li B, Jiang C, Xu Y, Fan X, Yang L, Zou B, et al. Genome-wide DNA methylation signature predict clinical benefit of bevacizumab in non-small cell Lung cancer. BMC Cancer. 2022;22(1):828.PubMedPubMedCentralCrossRef
32.
Hosaka K, Yang Y, Seki T, Du Q, Jing X, He X, et al. Therapeutic paradigm of dual targeting VEGF and PDGF for effectively treating FGF-2 off-target tumors. Nat Commun. 2020;11(1):3704.PubMedPubMedCentralCrossRefADS
33.
Koudijs KKM, van Terwisscha AGT, Bohringer S, Schimmel KJM, Guchelaar HJ. The impact of estimated tumour purity on gene expression-based drug repositioning of Clear Cell Renal Cell Carcinoma samples. Sci Rep. 2019;9(1):2495.PubMedPubMedCentralCrossRefADS
34.
Zhang S, Deng W, Liu Q, Wang P, Yang W, Ni W. Altered m(6) a modification is involved in up-regulated expression of FOXO3 in luteinized granulosa cells of non-obese polycystic ovary syndrome patients. J Cell Mol Med. 2020;24(20):11874–82.PubMedPubMedCentralCrossRef
35.
Hou G, Zhao X, Li L, Yang Q, Liu X, Huang C, et al. SUMOylation of YTHDF2 promotes mRNA degradation and cancer progression by increasing its binding affinity with m6A-modified mRNAs. Nucleic Acids Res. 2021;49(5):2859–77.PubMedPubMedCentralCrossRef
36.
Jiang Q, Cheng L, Ma D, Zhao Y. FBXL19-AS1 exerts oncogenic function by sponging mir-431-5p to regulate RAF1 expression in Lung cancer. Biosci Rep. 2019;39(1).
37.
Farzaneh Behelgardi M, Zahri S, Mashayekhi F, Mansouri K, Asghari SM. A peptide mimicking the binding sites of VEGF-A and VEGF-B inhibits VEGFR-1/-2 driven angiogenesis, Tumor growth and Metastasis. Sci Rep. 2018;8(1):17924.PubMedPubMedCentralCrossRefADS
38.
Yang T, Xiong Y, Zeng Y, Wang Y, Zeng J, Liu J, et al. Current status of immunotherapy for non-small cell Lung cancer. Front Pharmacol. 2022;13:989461.PubMedPubMedCentralCrossRef
39.
40.
41.
de Abrantes RA, Batista TM, Mangueira VM, de Sousa TKG, Ferreira RC, Moura APG, et al. Antitumor and antiangiogenic effects of Tonantzitlolone B, an uncommon diterpene from Stillingia Loranthacea. Naunyn Schmiedebergs Arch Pharmacol. 2022;395(2):267–74.PubMedCrossRef
42.
Folkman J. Antiangiogenesis in cancer therapy–endostatin and its mechanisms of action. Exp Cell Res. 2006;312(5):594–607.PubMedCrossRef
43.
Xu Z, Zhao X, Shu H, Luo W, Dong Y, Xu L, et al. Endostar synergizes with Radiotherapy to Inhibit Angiogenesis of Cervical Cancer in a Subcutaneous Xenograft Mouse Model. Front Biosci (Landmark Ed). 2022;27(8):238.PubMedCrossRef
44.
Svensson L, Narlid I, Oldberg A. Fibromodulin and lumican bind to the same region on collagen type I fibrils. FEBS Lett. 2000;470(2):178–82.PubMedCrossRef
45.
46.
Yang Y, Hsu PJ, Chen YS, Yang YG. Dynamic transcriptomic m(6)a decoration: writers, erasers, readers and functions in RNA metabolism. Cell Res. 2018;28(6):616–24.PubMedPubMedCentralCrossRef
47.
48.
Iaiza A, Tito C, Ianniello Z, Ganci F, Laquintana V, Gallo E, et al. METTL3-dependent MALAT1 delocalization drives c-Myc induction in thymic epithelial tumors. Clin Epigenetics. 2021;13(1):173.PubMedPubMedCentralCrossRef
49.
Yang DD, Chen ZH, Yu K, Lu JH, Wu QN, Wang Y, et al. METTL3 promotes the progression of gastric Cancer via targeting the MYC Pathway. Front Oncol. 2020;10:115.PubMedPubMedCentralCrossRef
50.
Wang N, Huo X, Zhang B, Chen X, Zhao S, Shi X, et al. METTL3-Mediated ADAMTS9 suppression facilitates angiogenesis and carcinogenesis in gastric Cancer. Front Oncol. 2022;12:861807.PubMedPubMedCentralCrossRef
51.
Wang G, Dai Y, Li K, Cheng M, Xiong G, Wang X, et al. Deficiency of Mettl3 in Bladder Cancer stem cells inhibits Bladder Cancer Progression and Angiogenesis. Front Cell Dev Biol. 2021;9:627706.PubMedPubMedCentralCrossRef
Metadata
Title
Multi-omics sequencing revealed endostar combined with cisplatin treated non small cell lung cancer via anti-angiogenesis
Authors
Yufei Wang
Hong Ren
Publication date
01-12-2024
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2024
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-023-11665-w

Other articles of this Issue 1/2024

BMC Cancer 1/2024 Go to the issue

Research

Identification of prognostic signatures in remnant gastric cancer through an interpretable risk model based on machine learning: a multicenter cohort study

Research

Binimetinib in combination with nivolumab or nivolumab and ipilimumab in patients with previously treated microsatellite-stable metastatic colorectal cancer with RAS mutations in an open-label phase 1b/2 study

Research

FBXO28 promotes cell proliferation, migration and invasion via upregulation of the TGF-beta1/SMAD2/3 signaling pathway in ovarian cancer

Research

Systematic optimization and evaluation of culture conditions for the construction of circulating tumor cell clusters using breast cancer cell lines

Research

Methyl CpG binding protein MBD2 has a regulatory role on the BRCA1 gene expression and its modulation by resveratrol in ER+, PR+ & triple-negative breast cancer cells

Research

High expression of TBRG4 in relation to unfavorable outcome and cell ferroptosis in hepatocellular carcinoma
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits